RMC-6236 + gemcitabine + nab-paclitaxel

**RMC-6236 + gemcitabine + nab-paclitaxel** is an investigational combination therapy primarily under evaluation for the treatment of pancreatic ductal adenocarcinoma and potentially other RAS-driven solid tumors. - **RMC-6236** is an orally available, small molecule, “molecular glue” inhibitor that induces a non-physiological complex between cyclophilin A and active, GTP-bound RAS (including both mutant and wild-type isoforms), disrupting RAS signaling, especially in KRAS-driven cancers[1][3][5][7]. - **Gemcitabine** is a nucleoside analog used as a cytotoxic antimetabolite that inhibits DNA synthesis, leading to cell death in rapidly dividing cells. - **Nab-paclitaxel** is a nanoparticle albumin-bound formulation of paclitaxel, which stabilizes microtubules and inhibits cell division; albumin facilitates drug delivery to tumors[2][4][6]. This combination leverages RMC-6236’s targeted RAS inhibition with the established cytotoxic synergy and improved tumor delivery of gemcitabine and nab-paclitaxel, which is already approved for pancreatic cancer. There are ongoing clinical trials of this precise combination for RAS-mutant pancreatic cancers.

Other names

RMC-6236 + gemcitabine + albumin-bound paclitaxel